Description:
An agonist of TLR7 with immune response modifying activity, Approved for basal cell carcinoma, In Phase III for VIN and CIN, Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells.
- Molecular Weight: 240.30
- Molecular Formula: C14H16N4
Purity: >98%
Canonical SMILES:
CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
InChI:
InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
InChIKey: DOUYETYNHWVLEO-UHFFFAOYSA-N
- Boiling Point: 456.7±48.0°C at 760 mmHg
- Melting Point: 292-294°C
- Solubility: Soluble in Aqueous Acid (Slightly), DMSO (Very Slightly, Heated)
- Appearance: Off-White Solid
- Application: An immune response modifier. It stimulates the production of interferon-a
- Storage: Store at -20°C
Synonyms:
1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; R-837; S-26308; Aldara; TMX-101; 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine; Aldara; Beselna; Keravort; R 837; R837; S 26308; TMX 101; Zartra; Zyclara
More details are to be found on supplier website
